东吴证券给予仙乐健康“买入”评级：笃志力行，驭变成势

Group 1 - The core viewpoint of the article is that Dongwu Securities has given a "Buy" rating to Xianle Health (300791.SZ) based on its leadership in the health supplement CDMO sector and favorable market conditions [1] - Xianle Health is recognized as a leading enterprise in the health supplement CDMO (Contract Development and Manufacturing Organization) industry [1] - The health supplement industry is characterized by decentralized development, which benefits the CDMO segment [1] - The company has a global perspective, with stable growth in Europe and improving conditions in the Americas [1] - The importance of new retail customers is increasing for the company [1]